The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Psoriasis induced by anti–tumor necrosis factor therapy: A paradoxical adverse reaction
Abstract
Administration of anti–tumor necrosis factor (anti‐TNF) agents is beneficial in a variety of chronic inflammatory conditions, including psoriasis. We describe 5 patients in whom psoriasiform skin lesions developed 6–9 months after the initiation of anti‐TNF therapy for longstanding, seropositive rheumatoid arthritis (etanercept or adalimumab), typical ankylosing spondylitis (infliximab), and Adamantiades‐Behçet's disease (infliximab). In all 5 patients, the underlying disease had responded well to anti‐TNF therapy. Four patients developed a striking pustular eruption on the palms and/or soles accompanied by plaque‐type psoriasis at other skin sites, while 1 patient developed thick erythematous scaly plaques localized to the scalp. In 3 patients there was nail involvement with onycholysis, yellow discoloration, and subungual keratosis. Histologic findings from skin biopsies were consistent with psoriasis. None of these patients had a personal or family history of psoriasis. In all patients, skin lesions subsided either with topical treatment alone, or after discontinuation of the responsible anti‐TNF agent. The interpretation of this paradoxical side effect of anti‐TNF therapy remains unclear but may relate to altered immunity induced by the inhibition of TNF activity in predisposed individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Psoriatic arthritis: epidemiology, clinical features, course, and outcome
Gladman, D. D., Antoni, C., Mease, P., Clegg, D. O., & Nash, P. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.032482 · Cited by 1,536
Berg, E. L., Yoshino, T., Rott, L. S., Robinson, M. K., Warnock, R. A., Kishimoto, T. K., Picker, L. J., & Butcher, E. C. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.6.1461 · Cited by 548
Flier, J., Boorsma, D. M., van Beek, P. J., Nieboer, C., Stoof, T. J., Willemze, R., & Tensen, C. P. (2001) · The Journal of Pathology · doi:10.1002/1096-9896(200108)194:4<397::aid-path899>3.0.co;2-s · Cited by 363
Infliximab for Recurrent, Sight-Threatening Ocular Inflammation in Adamantiades–Behçet Disease
Sfikakis, P. P., Kaklamanis, P. H., Elezoglou, A., Katsilambros, N., Theodossiadis, P. G., Papaefthimiou, S., & Markomichelakis, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00025 · Cited by 229
Self-citationRottman, J. B., Smith, T. L., Ganley, K. G., Kikuchi, T., & Krueger, J. G. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780242 · Cited by 213
Baeten, D., Kruithof, E., Van den Bosch, F., Van den Bossche, N., Herssens, A., Mielants, H., De Keyser, F., & Veys, E. M. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.9.829 · Cited by 186
Beuthien, W., Mellinghoff, H.-U., & von Kempis, J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20155 · Cited by 110
Psoriasis treatment: current and emerging directed therapies
Winterfield, L. S., Menter, A., Gordon, K., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.032276 · Cited by 104
Psoriasiform Eruption Induced by Infliximab
Verea, M. M., del Pozo, J., Yebra-Pimentel, M. T., Porta, A., & Fonseca, E. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c477 · Cited by 103
TNFα therapy in psoriatic arthritis and psoriasis
Mease, P. J. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.020719 · Cited by 96
Aeberli, D., Seitz, M., Jüni, P., & Villiger, P. M. (2004) · Rheumatology · doi:10.1093/rheumatology/keh437 · Cited by 90
Pustular psoriasis induced by infliximab.
Thurber, M., Feasel, A. M., Stroehlein, J., & Hymes, S. R. (2004) · PubMed · Cited by 78
Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases
Dereure, O., Guillot, B., Jørgensen, C., Cohen, J.-D., Combes, B., & Guilhou, J. J. (2004) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.06107.x · Cited by 71
Tumor necrosis factor biology in experimental and clinical arthritis
Sfikakis, P. P., & Kollias, G. A. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200307000-00003 · Cited by 64
Self-citation
Cited by
Levy-Clarke, G., Jabs, D. A., Read, R. W., Rosenbaum, J. T., Vitale, A., & Van Gelder, R. N. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.048 · Cited by 483
Fidder, H., Schnitzler, F., Ferrante, M., Noman, M., Katsanos, K., Segaert, S., Henckaerts, L., Van Assche, G., Vermeire, S., & Rutgeerts, P. (2009) · Gut · doi:10.1136/gut.2008.163642 · Cited by 449
de Gannes, G. C., Ghoreishi, M., Pope, J., Russell, A., Bell, D., Adams, S., Shojania, K., Martinka, M., & Dutz, J. P. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.2.223 · Cited by 325
Conrad, C., Di Domizio, J., Mylonas, A., Belkhodja, C., Demaria, O., Navarini, A. A., Lapointe, A.-K., French, L. E., Vernez, M., & Gilliet, M. (2018) · Nature Communications · doi:10.1038/s41467-017-02466-4 · Cited by 317
Ko, J. M., Gottlieb, A. B., & Kerbleski, J. F. (2009) · Journal of Dermatological Treatment · doi:10.1080/09546630802441234 · Cited by 313
Metadata
- Authors
- Sfikakis, P. P., Iliopoulos, A., Elezoglou, A., Kittas, C., & Stratigos, A.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-07-28
- Volume
- 52
- Issue
- 8
- Pages
- 2513-2518
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2047295530
- Cited by
- 301
- References
- 15
- FWCI
- 9.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.